218 related articles for article (PubMed ID: 29577257)
1. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation.
Serna MJ; Rivera-Caravaca JM; Gonzalez-Conejero R; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Roldán V; Marín F
Eur J Clin Invest; 2018 Jun; 48(6):e12929. PubMed ID: 29577257
[TBL] [Abstract][Full Text] [Related]
2. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics role in the safety of acenocoumarol therapy.
Jiménez-Varo E; Cañadas-Garre M; Henriques CI; Pinheiro AM; Gutiérrez-Pimentel MJ; Calleja-Hernández MÁ
Thromb Haemost; 2014 Sep; 112(3):522-36. PubMed ID: 24919870
[TBL] [Abstract][Full Text] [Related]
4. Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project.
Esteve-Pastor MA; Rivera-Caravaca JM; Roldan V; Vicente V; Valdés M; Marín F; Lip GYH
Thromb Haemost; 2017 Oct; 117(10):1848-1858. PubMed ID: 28799620
[TBL] [Abstract][Full Text] [Related]
5. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
[TBL] [Abstract][Full Text] [Related]
6. Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms.
Bryk AH; Wypasek E; Plens K; Awsiuk M; Undas A
Vascul Pharmacol; 2018 Jul; 106():22-27. PubMed ID: 29432897
[TBL] [Abstract][Full Text] [Related]
7. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study.
Apostolakis S; Lane DA; Guo Y; Buller H; Lip GY
J Am Coll Cardiol; 2012 Aug; 60(9):861-7. PubMed ID: 22858389
[TBL] [Abstract][Full Text] [Related]
8. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
[TBL] [Abstract][Full Text] [Related]
9. Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation.
Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Marín F
Sci Rep; 2017 Sep; 7(1):12066. PubMed ID: 28935868
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.
Nagler M; Angelillo-Scherrer A; Méan M; Limacher A; Abbal C; Righini M; Beer JH; Osterwalder J; Frauchiger B; Aschwanden M; Matter CM; Kucher N; Cornuz J; Banyai M; Husmann M; Staub D; Mazzolai L; Hugli O; Rodondi N; Aujesky D
J Thromb Haemost; 2017 Nov; 15(11):2165-2175. PubMed ID: 28834238
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the CHA
Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA
Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514
[TBL] [Abstract][Full Text] [Related]
12. The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients.
Montes R; Nantes O; Alonso A; Zozaya JM; Hermida J
Br J Haematol; 2008 Dec; 143(5):727-33. PubMed ID: 18950464
[TBL] [Abstract][Full Text] [Related]
13. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
O'Brien EC; Simon DN; Thomas LE; Hylek EM; Gersh BJ; Ansell JE; Kowey PR; Mahaffey KW; Chang P; Fonarow GC; Pencina MJ; Piccini JP; Peterson ED
Eur Heart J; 2015 Dec; 36(46):3258-64. PubMed ID: 26424865
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HAS-BLED and HAS-BED Versus CHADS
Poli D; Antonucci E; Pengo V; Testa S; Palareti G
Am J Cardiol; 2017 Apr; 119(7):1012-1016. PubMed ID: 28237286
[TBL] [Abstract][Full Text] [Related]
15. Enhancing the 'real world' prediction of cardiovascular events and major bleeding with the CHA
Roldán V; Rivera-Caravaca JM; Shantsila A; García-Fernández A; Esteve-Pastor MA; Vilchez JA; Romera M; Valdés M; Vicente V; Marín F; Lip GYH
Ann Med; 2018 Feb; 50(1):26-34. PubMed ID: 28892413
[TBL] [Abstract][Full Text] [Related]
16. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
An SH; Lee KE; Chang BC; Gwak HS
J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
[TBL] [Abstract][Full Text] [Related]
17. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin.
Senoo K; Proietti M; Lane DA; Lip GY
Am J Med; 2016 Jun; 129(6):600-7. PubMed ID: 26482233
[TBL] [Abstract][Full Text] [Related]
19. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy.
Roldán V; Marín F; Fernández H; Manzano-Fernandez S; Gallego P; Valdés M; Vicente V; Lip GYH
Chest; 2013 Jan; 143(1):179-184. PubMed ID: 22722228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
